The Commissioning Support Programme closed on 1 June 2019.
The programme provided support to NHS England’s specialised services clinical commissioning policies for licensed medicines from November 2016 to May 2019.
The voluntary scheme for branded medicines pricing and access (published in November 2018) means that we no longer need to support the policy development process. The voluntary scheme states:
"All New Active Substances in their first indication, and extensions to their Marketing Authorisation to add a significant new therapeutic indication, will undergo an appropriate NICE appraisal, except where there is a clear rationale not to do so. NICE expects to achieve this by April 2020."
The Commissioning Support Programme completed its work in May 2019. You can find information about topics developed by the programme on the NHS England consultation hub.
NHS England will continue to develop specialised clinical commissioning policies for off-licence and off-label medicines and medicines receiving routine licence extensions which are not appraised by NICE. From the 1 June 2019, NHS England will also continue to develop Commissioning Support Programme topics which haven't been considered by the clinical priorities advisory group. If you have any questions about these policies, contact CET@nhsengland.net.
If you have any questions about the Commissioning Support Programme, contact email@example.com.